Les cônes marins, une ressource naturelle d’antalgiques venue du fond des mers : au-delà du ziconotide ?

Les cônes marins sont des animaux remarquables qui ont développé au cours de l’évolution des outils leur permettant de survivre et de se nourrir sous la mer quels que soient le prédateur ou la proie auxquels ils pourraient être confrontés. Leurs venins de prédation et de défense contiennent des centaines de peptides bioactifs dont l’ω- conotoxine ziconotide, première conotoxine thérapeutique utilisée dans le traitement des douleurs chroniques intenses et pharmacorésistantes aux traitements antalgiques recommandés comme la morphine. Cette revue fait le point sur le mode d’action du ziconotide et met en valeur d’autres composés de venins de cônes ayant un potentiel thérapeutique pour traiter les douleurs pathologiques.

• Publication year

  2019

• Venue

  Douleur et Analgésie

• Publication date

  2019-12-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.3166/dea-2020-0077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Open Label Study

  2020cited by this paper
• RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats

  2019cited by this paper
• TAT-Modified ω-Conotoxin MVIIA for Crossing the Blood-Brain Barrier

  2019cited by this paper
• Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways.

  2019cited by this paper
• Nicotinic acetylcholine receptors in neuropathic and inflammatory pain

  2018cited by this paper
• Sodium channels and pain: from toxins to therapies

  2018cited by this paper
• Cyclic analogues of α‐conotoxin Vc1.1 inhibit colonic nociceptors and provide analgesia in a mouse model of chronic abdominal pain

  2018cited by this paper
• Cone Snails: A Big Store of Conotoxins for Novel Drug Discovery

  2017cited by this paper
• Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

  2017cited by this paper
• Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties

  2017cited by this paper
• Oxytocin Signaling in Pain: Cellular, Circuit, System, and Behavioral Levels.

  2017cited by this paper
• Molecular, Cellular and Circuit Basis of Cholinergic Modulation of Pain

  2017cited by this paper
• Phase IA Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Analgesic Efficacy of an Intrathecally Administered Neurotensin A Analogue in Central Neuropathic Pain Following Spinal Cord Injury

  2016cited by this paper
• Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations

  2015cited by this paper
• Painful and painless channelopathies.

  2014cited by this paper
• Spinal Coding of Itch and Pain

  2014cited by this paper
• Itch: Mechanisms and Treatment

  2014cited by this paper
• &agr;‐Conotoxin RgIA protects against the development of nerve injury‐induced chronic pain and prevents both neuronal and glial derangement

  2014cited by this paper
• Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails

  2014cited by this paper
• Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review.

  2013cited by this paper
• Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats

  2013cited by this paper
• Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α‐conotoxin RgIA

  2012cited by this paper
• Conus Venom Peptide Pharmacology

  2012cited by this paper
• Total synthesis of the analgesic conotoxin MrVIB through selenocysteine-assisted folding.

  2011cited by this paper
• Drugs from slugs--past, present and future perspectives of omega-conotoxin research.

  2010cited by this paper
• The engineering of an orally active conotoxin for the treatment of neuropathic pain.

  2010cited by this paper
• Long-term intrathecal ziconotide for chronic pain: an open-label study.

  2009cited by this paper
• Conopressin-T from Conus tulipa Reveals an Antagonist Switch in Vasopressin-like Peptides*

  2008cited by this paper
• Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.

  2008cited by this paper
• An Assessment of the Antinociceptive Efficacy of Intrathecal and Epidural Contulakin-G in Rats and Dogs

  2007cited by this paper
• Conotoxins containing nonnatural backbone spacers: cladistic-based design, chemical synthesis, and improved analgesic activity.

  2007cited by this paper
• The Pharmacokinetics of the Conopeptide Contulakin-G (CGX-1160) After Intrathecal Administration: An Analysis of Data from Studies in Beagles

  2007cited by this paper
• Ziconotide: a review of its pharmacology and use in the treatment of pain

  2007cited by this paper
• Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors

  2006cited by this paper
• μO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits

  2006cited by this paper
• Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors.

  2006cited by this paper
• Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

  2006cited by this paper
• Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones.

  2005cited by this paper
• Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain.

  2005cited by this paper
• SO‐3, a new O‐superfamily conopeptide derived from Conus striatus, selectively inhibits N‐type calcium currents in cultured hippocampal neurons

  2005cited by this paper
• Population pharmacokinetic and pharmacodynamic analysis of leflunomide in rheumatoid arthritis

  2004cited by this paper
• Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.

  2004cited by this paper
• Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.

  2004cited by this paper
• Powerful antinociceptive effects of the cone snail venom‐derived subtype‐selective NMDA receptor antagonists conantokins G and T

  2003cited by this paper
• The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus.

  2003cited by this paper
• Inhibition of the Norepinephrine Transporter by the Venom Peptide χ-MrIA

  2003cited by this paper
• χ-Conopeptide MrIA Partially Overlaps Desipramine and Cocaine Binding Sites on the Human Norepinephrine Transporter*

  2003cited by this paper
• A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo.

  2003cited by this paper
• Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat.

  2002cited by this paper
• Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter

  2001cited by this paper
• Ziconotide, A New N‐Type Calcium Channel Blocker, Administered Intrathecally for Acute Postoperative Pain

  2000cited by this paper
• Contulakin-G, an O-Glycosylated Invertebrate Neurotensin*

  1999cited by this paper
• Inactivation of a serotonin-gated ion channel by a polypeptide toxin from marine snails.

  1998cited by this paper
• Conopressin affects excitability, firing, and action potential shape through stimulation of transient and persistent inward currents in mulluscan neurons.

  1998cited by this paper
• Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain.

  1996cited by this paper
• Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC).

  1994cited by this paper
• Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium channel antagonist, SNX-230 (ω-conopeptide MVIIC)

  1994cited by this paper
• Characterization of the electrically evoked release of substance P from dorsal root ganglion neurons: methods and dihydropyridine sensitivity

  1988cited by this paper
• Neuronal calcium channel inhibitors. Synthesis of omega-conotoxin GVIA and effects on 45Ca uptake by synaptosomes.

  1987cited by this paper
• Invertebrate vasopressin/oxytocin homologs. Characterization of peptides from Conus geographus and Conus straitus venoms.

  1987cited by this paper
• A venom peptide with a novel presynaptic blocking action

  1984cited by this paper
• Purification and sequence of a presynaptic peptide toxin from Conus geographus venom.

  1984cited by this paper
• Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat

  1979cited by this paper
• Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli.

  1977cited by this paper
• FURTHER STUDIES OF THE VENOMS OF CONIDAE.

  1965cited by this paper
• Studies of the venoms of some Conidae

  1963cited by this paper
• The Ecology of Conus in Hawaii

  1959cited by this paper

• Neurophysiology of acute and chronic pain: from genes to pain symptoms.

  2025cites this paper